期刊名称：EXPERT REVIEW OF HEMATOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
Areas covered include:
• Acute leukemias
• Anemias
• Bleeding disorders
• Bone marrow and hematopoietic stem cell transplantation
• Cellular disorders
• Chronic leukemias
• Disorders of iron metabolism
• Hodgkins disease
• Infection in hematology
• Immunodeficiency syndromes
• Autoimmune diseases
• Marrow failure syndromes
• Multiple myeloma and amyloidosis
• Myeloproliferative disorders
• Neutropenia
• Non-Hodgkin lymphomas
• Pediatric hematology
• Platelet disorders
• Thrombosis and hemostasis
• Transfusion medicine
Expert Review of Hematology provides commentary and analysis to elucidate best clinical practice in hematology and to translate advances in research – in areas such as immunology, stem cell research, and cell and gene therapy – into the clinical context.
Indexing
Impact Factor: 0.459 (2010)
Chemical Abstracts
EMBASE/Excerpta Medica
Science Citation Index Expanded (SciSearch®)
MEDLINE/Index Medicus
Instructions to Authors
er_author_guidelines.pdf
Editorial Board
Editorial Staff
Launch Editor - Laura Dormer
Editorial Advisory Board
Aledort LM, Mount Sinai School of Medicine, NY, USA
Aplan P, NIH, National Cancer Institute, MD, USA
Ataga K, University of North Carolina, Chapel Hill, NC, USA
Byrd JC, The Ohio State University, OH, USA
Cappellini MD, University of Milan, Italy
Castaman G, San Bortolo Hospital, Italy
Cortes J, MD Anderson Cancer Center, TX, USA
Dimopoulos MA, University of Athens, Greece
Dreyling M, University of Munich, Germany
Engert A, University Hospital of Cologne, Germany
Giles FJ, Cancer Therapy & Research Center, TX, USA
Grever M, The Ohio State University, OH, USA
Harousseau JL, Centre Hospitalier Universitaire Hôtel-Dieu, France
Hochhaus A, University of Heidelberg, Germany
Lambertenghi Deliliers G, University of Milan, Italy
Leen AM, Baylor College of Medicine, TX, USA
Liras A, Universidad Complutense of Madrid, Spain
Machin SJ, University College London School of Medicine, UK
Murphy M, National Blood Service, UK
O’Connor O, Columbia University Medical Center, NY, USA
Orlowski RZ, The University of Texas MD Anderson Cancer Center, TX, USA
Palmblad J, Karolinska Institutet, Sweden
Pileri S, Bologna University School of Medicine, Italy
Prentice A, Royal Free Hospital, UK
Richardson P, Dana Farber Cancer Institute, MA, USA
Roboz GJ, Weill Medical College of Cornell University, NY, USA
Schiffer C, Barbara Ann Karmanos Cancer Institute, MI, USA
Stone RM, Dana Farber Cancer Institute, MA, USA
Valent P, Medical University of Vienna, Austria
|
